Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

Expert Opinion on Investigational Drugs
Barry I Eisenstein

Abstract

The increasing incidence of serious infections caused by antibiotic-resistant Gram-positive bacteria has led to the development of new spectrum-specific agents. One such agent is Cubicin (daptomycin for injection), the first member of a new class of antibacterials called cyclic lipopeptides. Daptomycin has rapid, concentration-dependent bactericidal activity against most clinically significant Gram-positive pathogens, including vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and vancomycin-intermediate and -resistant S. aureus. This cyclic lipopeptide has a unique mechanism of action and exhibits a relatively prolonged concentration-dependent postantibiotic effect in vitro. In September 2003 the US FDA approved daptomycin for the treatment of complicated skin and skin-structure infections. With its once-daily dosing, excellent safety profile and low potential for resistance, daptomycin is a welcome new addition to the armamentarium against Gram-positive infections.

References

Dec 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E BingenP Mariani-Kurkdjian
Nov 11, 1991·Antimicrobial Agents and Chemotherapy·W E AlbornD A Preston
Dec 11, 1991·Antimicrobial Agents and Chemotherapy·N E AllenJ N Hobbs
Apr 1, 1996·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·P Canepari, M Boaretti
May 21, 1999·Science·J W CostertonE P Greenberg
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·F B OlesonF P Tally
Nov 18, 2000·Antimicrobial Agents and Chemotherapy·D R SnydmanJ M Boyce
Apr 11, 2001·Emerging Infectious Diseases·H F Chambers
Apr 11, 2001·Emerging Infectious Diseases·F C TenoverM V Lancaster
May 17, 2001·Antimicrobial Agents and Chemotherapy·J A SilvermanT Li
May 17, 2001·Antimicrobial Agents and Chemotherapy·A L BarryS D Brown
Aug 2, 2001·The Journal of Antimicrobial Chemotherapy·A King, I Phillips
Feb 28, 2002·The Journal of Antimicrobial Chemotherapy·Peter C FuchsSteven D Brown
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cassandra D SalgadoDavid P Calfee
Feb 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott K FridkinUNKNOWN Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group
Apr 4, 2003·The New England Journal of Medicine·Soju ChangUNKNOWN Vancomycin-Resistant Staphylococcus aureus Investigative Team
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Jared A SilvermanHoward M Shapiro
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield
Jan 27, 2004·Pharmacotherapy·Kerry L Tedesco, Michael J Rybak
Feb 14, 2004·The Journal of Antimicrobial Chemotherapy·Kenneth H Rand, Herbert Houck
Mar 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher F Carpenter, Henry F Chambers
May 18, 2004·Journal of Clinical Pharmacology·Barry Dvorchik, David Damphousse
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert D ArbeitUNKNOWN Daptomycin 98-01 and 99-01 Investigators
Jul 17, 2004·Southern Medical Journal·Michael S Gelfand, Kerry O Cleveland
Jul 5, 2005·Expert Opinion on Investigational Drugs·F P TallyF B Oleson

❮ Previous
Next ❯

Citations

Sep 30, 2005·Journal of Industrial Microbiology & Biotechnology·Richard H BaltzStephen K Wrigley
Nov 2, 2005·Journal of Industrial Microbiology & Biotechnology·Julia PennRichard H Baltz
Feb 11, 2011·Current Infectious Disease Reports·Subramanian Swaminathan, George J Alangaden
Jan 10, 2009·The Journal of Antibiotics·Arnold L Demain, Sergio Sanchez
Nov 29, 2005·Natural Product Reports·Richard H BaltzStephen K Wrigley
Feb 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stan Deresinski
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·P M Hawkey
May 18, 2011·Antimicrobial Agents and Chemotherapy·Anne-K JohnRegine Landmann
Apr 20, 2011·Antimicrobial Agents and Chemotherapy·Ravina KullarMichael J Rybak
Mar 1, 2012·Therapeutics and Clinical Risk Management·Mao HagiharaHiroshige Mikamo
Dec 10, 2009·Vascular Health and Risk Management·Michael Edmonds
Nov 9, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kien T NguyenRichard H Baltz
Sep 8, 2010·Expert Review of Anti-infective Therapy·Daniel Curcio
Nov 1, 2007·Expert Opinion on Drug Discovery·Barry I Eisenstein
Jan 25, 2007·Expert Opinion on Investigational Drugs·Garyphallia Poulakou, Helen Giamarellou
Aug 10, 2007·Expert Opinion on Investigational Drugs·Roman Jerala
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Christos Kosmidis, Donald P Levine
Nov 2, 2006·Current Medical Research and Opinion·Javier Garau
Feb 4, 2014·Infectious Disease Clinics of North America·Kalpana Gupta, Nahid Bhadelia
Feb 1, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M J Rybak
Feb 6, 2008·Diagnostic Microbiology and Infectious Disease·Brian T TsujiMichael J Rybak
Dec 25, 2007·International Journal of Antimicrobial Agents·Nesrene S OmarJim Gray
Jul 25, 2007·The Lancet Infectious Diseases·Kevin OuttersonKaren Keller-Cuda
Sep 17, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·G Perera, R Hay
Mar 18, 2009·Medicinal Research Reviews·Arnold L Demain
Aug 12, 2009·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Pavani ReddyGary A Noskin
Oct 1, 2011·Wiley Interdisciplinary Reviews. RNA·Lisa S McCoyYitzhak Tor
Oct 16, 2007·The American Journal of Medicine·Kenneth C LampRene Russo
Oct 16, 2007·The American Journal of Medicine·Donald P Levine, Kenneth C Lamp
Sep 12, 2006·International Journal of Antimicrobial Agents·Glenn W KaatzSusan M Seo
Jan 21, 2006·International Journal of Antimicrobial Agents·Helen C Maltezou, Helen Giamarellou
Jul 17, 2008·Journal of Medical Microbiology·Madhukiran H MurthyZiba Jalali
Oct 9, 2018·The Journal of Antimicrobial Chemotherapy·Nicolas GrégoireOlivier Mimoz
Nov 27, 2018·Chembiochem : a European Journal of Chemical Biology·Boris SmolkinTimor Baasov
Jun 6, 2007·Clinical Orthopaedics and Related Research·Paul D HoltomLawrence V Friedrich

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Pharmacotherapy
Kerry L Tedesco, M J Rybak
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Christopher F Carpenter, Henry F Chambers
Expert Opinion on Pharmacotherapy
Kerry L LaPlante, M J Rybak
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
M J Rybak
© 2021 Meta ULC. All rights reserved